News & Events:VXRT

Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its executive officers, Andrei Floroiu, CEO, and Sean Tucker, CSO, are scheduled to present at the SVB Leerink CybeRx Series: Vaccine Forum on Monday, June 21, 2021 at 1:00 p.m. Eastern Time.

Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu, CEO and Sean Tucker, CSO of the Vaxart (VXRT) executive team are scheduled to present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 1:30 p.m. Eastern Time.

Vaxart Inc (VXRT): * VAXART ANNOUNCES FIRST SUBJECT ENROLLED IN PHASE 1B NOROVIRUS DOSE-RANGING TRIAL IN ELDERLY ADULTS. * Vaxart Inc (VXRT) - ALSO EXPECTS TO LAUNCH A PHASE 2 NOROVIRUS HUMAN CHALLENGE STUDY LATER THIS YEAR Source text for Eikon: Further company coverage:

Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population Norovirus represents a significant unmet need in the elderly — there currently is no approved vaccine. Safety and immunogenicity data to also inform oral COVID-19 vaccine program in older population.

Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate Norovirus infects 15% of U.S. children under age five every year. Study results may inform the COVID-19 oral vaccine program.

Vaxart Inc (VXRT): * NEW DATA FROM VAXART ORAL COVID-19 VACCINE PHASE I STUDY SUGGESTS BROAD CROSS-REACTIVITY AGAINST OTHER CORONAVIRUSES Source text for Eikon: Further company coverage:

Vaxart (VXRT) oral vaccine induced higher CD8+ T-Cell responses than those seen with Moderna or Pfizer vaccines in comparative experiment conducted by the Company IgA antibodies triggered in the mucosa, show broad cross-reactivity SOUTH SAN FRANCISCO, Calif., May 03, 2021 -- Vaxart (VXRT), Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rathe...

Vaxart Inc (VXRT): * VAXART REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q1 LOSS PER SHARE $0.14. * Q1 REVENUE $506,000. * CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $177.3 MILLION AS OF MARCH 31, 2021 Source text for Eikon: Further company coverage:

SOUTH SAN FRANCISCO, Calif., May 03, 2021 -- Vaxart (VXRT), Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by room-temperature stable tablet rather than by injection, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its founder and chief scientific officer, Sean Tucker, Ph.D., will present at the upcoming World Vaccine Congress Washington that will be held virtually from May 4-6, 2021.

Vaxart (VXRT) to provide new data from its Phase I COVID-19 trial Stanford University T-cell expert to discuss cross-protection against variants.

Vaxart Inc (VXRT): * VAXART APPOINTS DAVID WHEADON, M.D., TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Vaxart (VXRT), Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Wheadon, M.D., to its Board of Directors. “We welcome Dr. Wheadon to our Board of Directors,” said Andrei Floroiu, chief executive officer of Vaxart.

Nearly 19 million Americans who will decline vaccines would get vaccinated if they had a pill option, Vaxart’s poll finds Seven in 10 said they would prefer a pill over an injection Nearly 19 million more American adults – about a third of those now refusing to get vaccinated – would get vaccinated if they could take a pill instead of getting a shot, according to a poll conducted by Quadrant S...

NEW YORK, April 20, 2021  The Director of the U.S. National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, and many other experts have warned that rapid reopening and lifting of pandemic restrictions in many states, as well as the proliferation of more contagious variants, will likely result in ongoing and increased spread of the virus in hot spots around the country.

NEW YORK, March 24, 2021 Recent reports from across the country clearly show that infection cases are stabilizing. In the meantime, mass testing is crucial for governments to properly implement preventive measures throughout this pandemic.

NEW YORK, March 23, 2021  Since the pandemic's inception and the subsequent pressure the healthcare infrastructure faced, effective mass testing has been necessary to come up with a proper plan to reduce case numbers. Now that vaccines are available and are being rolled out, the worries of the pandemic are slightly receding.

Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference taking place on March 9-10, 2021.

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 -- Vaxart, Inc. (VXRT) a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it plans to initiate the first Phase 2 study of its oral COVID-19 vaccine candidate, VXA-CoV2-1, in 2Q 2021.

Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business update at 4:30 PM ET on Tuesday, March 2, 2021.